Most Read Articles
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

3 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

Rifabutin-based triple therapy wipes out H. pylori in infected patients

13 May 2020

The novel rifabutin-based triple therapy (RHB-105) delivers promising outcomes as first-line empirical treatment for Helicobacter pylori eradication, according to the results of a phase III, double blind trial. This therapy addresses the challenge of rising antibiotic resistance in the current environment.

This trial included 455 treatment-naïve adults with epigastric discomfort and confirmed H. pylori infection in 55 clinical research sites in the US. Participants were randomized to receive RHB-105 (amoxicillin 3 g; omeprazole 120 mg; rifabutin 150 mg) or an active comparator (amoxicillin 3 g and omeprazole 120 mg), given as four capsules every 8 hours for 14 days.

The investigators used the χ2 test to analyse between-group difference for H. pylori eradication rate, as demonstrated by 13C urea breath test 4 weeks after treatment.

The intention-to-treat analysis revealed a higher eradication rate with RHB-105 (n=228; 83.8 percent, 95 percent confidence interval [CI], 78.4–88.0 percent) than with the active comparator (n=227; 57.7 percent, 95 percent CI, 51.2–64.0 percent; p<0.001).

Resistance to clarithromycin or metronidazole did not affect the eradication rates. In addition, no resistance to rifabutin was observed.

Adverse events that were commonly reported for the two therapies were as follows: diarrhoea (RHB-105 vs active comparator: 10.1 percent vs 7.9 percent), headache (7.5 percent vs 7 percent) and nausea (4.8 percent vs 5.3 percent).

This study was limited by its exclusion of patients of Asian descent due to their higher prevalence of poor cytochrome P450 2C19 metabolizers, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

3 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.